Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
SZSE:301130.SZ
28.32 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 256.405 | 225.491 | 255.468 | 285.656 | 286.319 | 324.914 | 280.203 | 273.508 | 203.556 | 192.69 | 151.305 | 115.691 |
| Cost of Revenue
| 60.192 | 44.501 | 46.924 | 46.703 | 43.911 | 46.536 | 37.88 | 34.759 | 29.423 | 55.686 | 53.142 | 48.609 |
| Gross Profit
| 196.213 | 180.991 | 208.544 | 238.953 | 242.407 | 278.378 | 242.323 | 238.748 | 174.134 | 137.004 | 98.163 | 67.082 |
| Gross Profit Ratio
| 0.765 | 0.803 | 0.816 | 0.837 | 0.847 | 0.857 | 0.865 | 0.873 | 0.855 | 0.711 | 0.649 | 0.58 |
| Reseach & Development Expenses
| 10.224 | 8.7 | 11.743 | 13.314 | 4.366 | 16.563 | 20.554 | 11.989 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 8.995 | 8.177 | 6.635 | 4.858 | -37.432 | -66.891 | -55.556 | -5.091 | 33.571 | 24.282 | 19.279 | 15.129 |
| Selling & Marketing Expenses
| 109.302 | 113.06 | 133.635 | 152.953 | 164.526 | 177.572 | 153.431 | 154.281 | 92.504 | 69.236 | 38.945 | 19.934 |
| SG&A
| 118.296 | 120.884 | 140.27 | 157.812 | 127.094 | 110.681 | 97.876 | 149.19 | 126.074 | 93.517 | 58.224 | 35.062 |
| Other Expenses
| 21.358 | -4.598 | -1.698 | -0.463 | -5.981 | -8.109 | -8.384 | -0.897 | 5.14 | 7.443 | 6.863 | 3.084 |
| Operating Expenses
| 149.879 | 124.319 | 168.438 | 182.577 | 183.759 | 211.457 | 187.815 | 185.67 | 129.552 | 96.394 | 60.376 | 36.318 |
| Operating Income
| 46.335 | 55.651 | 52.128 | 59.67 | 59.244 | 65.421 | 48.509 | 54.176 | 55.019 | 40.564 | 37.248 | 30.552 |
| Operating Income Ratio
| 0.181 | 0.247 | 0.204 | 0.209 | 0.207 | 0.201 | 0.173 | 0.198 | 0.27 | 0.211 | 0.246 | 0.264 |
| Total Other Income Expenses Net
| 0.18 | 2.661 | -1.698 | -0.463 | -0.317 | -1.011 | -0.174 | -0 | 5.14 | 7.443 | 6.863 | 3.084 |
| Income Before Tax
| 46.515 | 58.313 | 50.431 | 59.207 | 58.927 | 64.41 | 48.335 | 54.175 | 60.159 | 48.007 | 44.111 | 33.636 |
| Income Before Tax Ratio
| 0.181 | 0.259 | 0.197 | 0.207 | 0.206 | 0.198 | 0.173 | 0.198 | 0.296 | 0.249 | 0.292 | 0.291 |
| Income Tax Expense
| 6.246 | 7.81 | 9.708 | 7.187 | 9.184 | 9.797 | 6.975 | 8.55 | 9.241 | 7.689 | 6.866 | 5.382 |
| Net Income
| 40.269 | 50.502 | 40.723 | 52.019 | 49.742 | 54.613 | 41.36 | 45.625 | 50.917 | 40.318 | 37.245 | 28.254 |
| Net Income Ratio
| 0.157 | 0.224 | 0.159 | 0.182 | 0.174 | 0.168 | 0.148 | 0.167 | 0.25 | 0.209 | 0.246 | 0.244 |
| EPS
| 0.52 | 0.62 | 0.5 | 0.64 | 0.62 | 0.68 | 0.68 | 0.8 | 0.94 | 0.74 | 0.69 | 0.64 |
| EPS Diluted
| 0.52 | 0.62 | 0.5 | 0.64 | 0.62 | 0.68 | 0.68 | 0.8 | 0.94 | 0.74 | 0.69 | 0.64 |
| EBITDA
| 69.117 | 76.986 | 58.594 | 77.92 | 79.421 | 85.119 | 66.31 | 66.417 | 44.582 | 41.172 | 38.278 | 30.764 |
| EBITDA Ratio
| 0.27 | 0.341 | 0.229 | 0.273 | 0.277 | 0.262 | 0.237 | 0.243 | 0.219 | 0.214 | 0.253 | 0.266 |